Patents by Inventor Satoshi Obika

Satoshi Obika has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240240183
    Abstract: A problem to be solved by the present invention is to provide a double-stranded nucleic acid complex having a reduced toxicity whose effectiveness is not impaired. Provided is a double-stranded nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein: said first nucleic acid strand is capable of hybridizing to at least part of a target gene or a transcription product thereof, and has an antisense effect on said target gene or transcription product thereof, said second nucleic acid strand comprises a base sequence complementary to said first nucleic acid strand, and said first nucleic acid strand and/or said second nucleic acid strand comprises at least one bridged non-natural nucleoside represented by formula (I) or formula (II) (wherein R represents a hydrogen atom or a methyl group).
    Type: Application
    Filed: May 24, 2022
    Publication date: July 18, 2024
    Applicants: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Takanori YOKOTA, Tetsuya NAGATA, Kotaro YOSHIOKA, Satoshi OBIKA
  • Publication number: 20240240176
    Abstract: A prophylactic or therapeutic agent for a myopathy, including a miR-33b inhibitor, preferably an antisense oligonucleotide against miR-33b, as an effective component.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 18, 2024
    Applicants: KYOTO UNIVERSITY, OSAKA UNIVERSITY
    Inventors: Jun KOTERA, Koh ONO, Takahiro HORIE, Naoya SOWA, Yuya IDE, Satoshi OBIKA, Yuya KASAHARA
  • Publication number: 20240158790
    Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
    Type: Application
    Filed: December 21, 2023
    Publication date: May 16, 2024
    Applicants: National University Corporation Tokyo Medical and Dental University, Osaka University
    Inventors: Takanori Yokota, Kazutaka Nishina, Satoshi Obika, Hidehiro Mizusawa
  • Publication number: 20240148775
    Abstract: An oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention contains a nucleotide sequence complementary to a continuous sequence of at least 12 bases in a target region constituted by a base sequence of SEQ ID No. 1, and induces N-exon skipping in human REST pre-mRNA processing. Such oligonucleotides are useful for manufacturing medicines for treatment of cancer, for example.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 9, 2024
    Applicant: Osaka University
    Inventors: Masahito SHIMOJO, Satoshi OBIKA, Keishiro MISHIMA, Misa YOSHIDA
  • Patent number: 11905308
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: February 20, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba
  • Patent number: 11866705
    Abstract: Disclosed is an oligonucleotide or a pharmacologically acceptable salt thereof, wherein the oligonucleotide comprises at least one defined nucleoside structure, can bind to a human nSR100 gene and has human nSR100 expression inhibiting activity. The oligonucleotide has a length of 12 to 20 mer, and is complementary to a defined target region. Further, disclosed is an nSR100 gene expression inhibitor and a cancer therapeutic agent containing the oligonucleotide or the pharmacologically acceptable salt thereof. The cancer therapeutic agent is used for treatment of small cell lung cancer, prostate cancer, or breast cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 9, 2024
    Assignees: Osaka Univerity, National Institutes of Biomedical Innovation, Health and Nutrition, Luxna Biotech Co., Ltd.
    Inventors: Masahito Shimojo, Satoshi Obika, Yuya Kasahara, Takao Suzuki, Masaki Yamagami, Tadashi Umemoto
  • Publication number: 20230340008
    Abstract: Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The bridged nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The bridged nucleoside also has excellent industrial productivity.
    Type: Application
    Filed: February 18, 2021
    Publication date: October 26, 2023
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Hibiki KOMINE, Takaya SUGIURA, Takao INOUE, Tokuyuki YOSHIDA
  • Publication number: 20230159924
    Abstract: A prophylactic or therapeutic agent for an aneurysm comprising a miR-33b inhibiting substance, preferably an antisense oligonucleotide against miR-33b, as an active ingredient.
    Type: Application
    Filed: March 2, 2021
    Publication date: May 25, 2023
    Applicants: MITSUBISHI TANABE PHARMA CORPORATION, KYOTO UNIVERSITY, OSAKA UNIVERSITY, NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION
    Inventors: Jun KOTERA, Koh ONO, Takahiro HORIE, Tomohiro YAMASAKI, Satoshi KOYAMA, Satoshi OBIKA, Yuya KASAHARA
  • Publication number: 20230124641
    Abstract: A cross-linked nucleoside of the present invention is a compound represented by the formula (I) below. The cross-linked nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The cross-linked nucleoside also has excellent industrial productivity.
    Type: Application
    Filed: February 17, 2021
    Publication date: April 20, 2023
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Yota SAKURAI, Chika YAMAMOTO, Kei SUGITA, Takao INOUE, Tokuyuki YOSHIDA
  • Publication number: 20230113556
    Abstract: The present invention provides an antisense oligomer having the base sequence depicted in SEQ ID NO: 26, an antisense oligomer having a base sequence resulting from substitution, deletion, insertion, or addition of 1 to 6 bases in the base sequence depicted in SEQ ID NO: 26, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, an oligonucleotide conjugate in which the antisense oligomer is bound with a molecule capable of binding to an asialoglycoprotein receptor, and a pharmaceutical composition containing the same.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 13, 2023
    Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, OSAKA UNIVERSITY
    Inventors: Mariko SHIBA, Tsuyoshi YAMAMOTO, Fumito WADA, Tadayuki KOBAYASHI, Keisuke TACHIBANA, Satoshi OBIKA
  • Publication number: 20220372060
    Abstract: Disclosed are a 5?-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5?-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5?-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.
    Type: Application
    Filed: January 31, 2020
    Publication date: November 24, 2022
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Takaki HABUCHI, Go KATO, Takao INOUE, Tokuyuki YOSHIDA, Takaya SUGIURA
  • Patent number: 11479773
    Abstract: The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: October 25, 2022
    Assignees: Aichi Medical University, National Institutes of Biomedical Innovation, Health and Nutrition
    Inventors: Satoshi Obika, Yuya Kasahara, Kosei Takeuchi
  • Publication number: 20220282248
    Abstract: A nucleic acid medicine using an antisense nucleic acid to inhibit the expression of SYT13, which has better efficacy than siRNA for targeting peritoneal dissemination of gastric cancer is provided. An antisense oligonucleotide which consists of a nucleotide sequence substantially complementary to the nucleotide sequence of a specific region in human SYT13 mRNA and which can inhibit the expression of human SYT13 mRNA; and a pharmaceutical composition comprising the antisense oligonucleotide are also provided.
    Type: Application
    Filed: August 27, 2020
    Publication date: September 8, 2022
    Applicants: National University Corporation Tokai National Higher Education and Research System, National Institutes of Biomedical Innovation, Health and Nutrition
    Inventors: Mitsuro KANDA, Satoshi OBIKA, Yuya KASAHARA
  • Publication number: 20220177509
    Abstract: Provided is a method for producing a compound represented by formula (III) from a compound represented by formula (I) as a starting material.
    Type: Application
    Filed: March 31, 2020
    Publication date: June 9, 2022
    Applicants: NIPPON SHOKUBAI CO., LTD., OSAKA UNIVERSITY
    Inventors: Takeshi BABA, Hiroshi OKAMOTO, Yumi NOMURA, Satoshi OBIKA, Takao YAMAGUCHI
  • Publication number: 20220170020
    Abstract: The present invention aims to provide an antisense oligonucleic acid with reduced hepatotoxicity. The antisense oligonucleic acid according to the present invention is characterized in that it has a base length of not less than 7 nt and not more than 30 nt, wherein nucleic acid residues of not less than 1 nt and not more than 5 nt respectively from the both terminals are 2?,4?-bridged nucleic acids, 2?,4?-non-bridged nucleic acid residue(s) is(are) present between the above-mentioned both terminals, and one or more bases in the nucleic acid residue(s) of the above-mentioned 2?,4?-non-bridged nucleic acid residue(s) is/are modified.
    Type: Application
    Filed: February 7, 2022
    Publication date: June 2, 2022
    Applicant: Osaka University
    Inventors: Satoshi OBIKA, Reiko WAKI, Takao INOUE, Tokuyuki YOSHIDA, Kunihiko MORIHIRO, Yuya KASAHARA, Atsushi MIKAMI
  • Publication number: 20220169671
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Application
    Filed: February 9, 2022
    Publication date: June 2, 2022
    Applicant: Osaka University
    Inventors: Satoshi OBIKA, Kosuke ITO, Takaki HABUCHI, Masahiko HORIBA
  • Publication number: 20220160880
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Application
    Filed: February 3, 2022
    Publication date: May 26, 2022
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura
  • Publication number: 20220127300
    Abstract: Disclosed are a 5?-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5?-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5?-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.
    Type: Application
    Filed: February 10, 2020
    Publication date: April 28, 2022
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Takaki HABUCHI, Go KATO, Takao INOUE, Tokuyuki YOSHIDA, Md Ariful ISLAM
  • Patent number: 11286275
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 29, 2022
    Assignee: Osaka University
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba
  • Patent number: 11273222
    Abstract: Provided is an oligonucleotide conjugate comprising an oligonucleotide and two or more linearly connected asialoglycoprotein receptor-binding molecules attached to the oligonucleotide, wherein the oligonucleotide comprises a locked nucleoside analog having a bridging structure between the 4? and 2? positions, is complementary to a human PCSK9 gene, and has inhibitory activity on the expression of the human PCSK9 gene. The oligonucleotide conjugate of the present invention can be used in the field of pharmaceutical products, in particular, the field of the development and production of therapeutic agents for diseases associated with a high LDL cholesterol level.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: March 15, 2022
    Assignee: National Cerebral and Cardiovascular Center
    Inventors: Mariko Harada-Shiba, Fumito Wada, Satoshi Obika, Tsuyoshi Yamamoto, Keisuke Tachibana, Tadayuki Kobayashi, Kosuke Ito, Motoki Sawamura